Liontown
Liontown’s FY26 headline result was weak, but the investment case now hinges much more on FY27 execution and lithium prices than FY26 earnings.
- FY26 EBITDA disappointed badly: A$147m, around 29% below consensus. The NPAT beat isn’t particularly meaningful because it was driven largely by the A$113m deferred tax asset, rather than better operations.
- Cash flow is the bright spot: A$182m operating cash flow and A$561m year-end cash materially strengthen the balance sheet.
- Kathleen Valley is progressing: 392kt concentrate production was within guidance, plant availability reached 92%, and June-quarter recovery improved to 63%.
- FY27 costs are the major concern: guidance of A$1,050–1,250/t versus FY26’s A$987/t means investors aren’t yet seeing the operating leverage you’d normally expect as production ramps.
- Capex is substantial: A$320–370m in FY27, and importantly this does not include the full expansion capital associated with the next Kathleen Valley expansion.
- Next major catalyst: the refreshed feasibility study and FID for expansion beyond 2.8Mtpa, expected by end-September 2026.
Investment view
I wouldn’t put too much weight on the FY26 earnings miss itself. The more important question is whether Kathleen Valley can transition from a capital-intensive ramp-up story into a genuinely low-cost, high-cash-generating lithium operation.
The improving lithium price is helping considerably. If lithium remains strong, LTR’s A$561m cash position gives it substantially more flexibility to fund expansion without putting the balance sheet under immediate pressure. But if the September expansion study reveals significantly higher capital requirements, the market could quickly refocus on funding and returns.
